Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Graft engineering.

S J Noga1

  • 1Department of Oncology, Johns Hopkins Oncology Center, Baltimore, MD 21205, USA.

Seminars in Oncology
|July 6, 2000
PubMed
Summary
This summary is machine-generated.

Hematopoietic stem cell transplantation has advanced, improving cure rates and quality of life. Graft engineering strategies aim to reduce complications and enhance long-term remission in transplantation patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma.

Journal of clinical pharmacy and therapeutics·2017
Same author

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.

Leukemia·2010
Same author

High incidence of graft failure in children receiving CD34+ augmented elutriated allografts for nonmalignant diseases.

Bone marrow transplantation·2003
Same author

Current methods and new developments in graft evaluation.

Cytotherapy·2002
Same author

Using point-of-care CD34 enumeration to optimize PBSC collection conditions.

Cytotherapy·2002
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Advances in supportive care, antimicrobials, and immunosuppression have improved hematopoietic stem cell transplantation (HSCT) outcomes.
  • Reduced graft-versus-host disease has lowered morbidity in allogeneic HSCT.
  • Use of unrelated donors, peripheral blood stem cells, and HLA-mismatched donors introduces new complications.

Purpose of the Study:

  • To evaluate the efficacy of graft engineering in reducing long-term complications of HSCT.
  • To analyze 12 years of clinical trial data on graft engineering strategies.
  • To explore future directions in transplantation and alternative therapies.

Main Methods:

  • Stepwise manipulation of hematopoietic grafts and host immune properties.

Related Experiment Videos

  • Utilized successive clinical protocols with defined outcome parameters.
  • Reviewed 12 years of clinical trial data from a single center.

    • Main Results:

    • Graft engineering demonstrated potential in managing HSCT complications.
    • Allogeneic HSCT offers better long-term remission than autologous HSCT, despite higher initial morbidity.
    • Autologous HSCT has minimal post-transplantation morbidity but inferior remission rates.

    Conclusions:

    • Graft engineering is a promising approach to mitigate HSCT complications.
    • Continued research is needed to optimize graft engineering techniques.
    • Future innovations may offer alternatives to current transplantation methods.